TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04322006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ004309
Description: Antibody to CD73

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Humanized monoclonal antibody to PD-1
Study: NCT01873573

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Description: EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Description: EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
Study: NCT03452488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO101
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO101
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT04009668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab will be dosed based on weight
Study: NCT04168502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Patients will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
Study: NCT01159990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAd5 Gag-Pol Env A/B/C
Description: 1×10\^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
Study: NCT00692471

Intervention type: DEVICE
Intervention: Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter
Description: Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.

Intervention type: DEVICE
Intervention: Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter
Description: Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
Study: NCT03583541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Risk Reduction
Description: This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Risk Reduction
Description: This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Risk Reduction
Description: This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy
Description: This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 \& 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 \& 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy
Description: This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 \& 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 \& 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
Study: NCT01159990

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rAd5 Gag-Pol
Description: 5×10\^9 PU rAd5 Gag-Pol delivered via intramuscular injection
Study: NCT02210611

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination 36 hours
Description: Intrauterine insemination 36 hours after ovulation induction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination 42 hours
Description: Intrauterine insemination 42 hours after ovulation induction
Study: NCT02813356

Intervention type: DRUG
Intervention: naloxegol
Description: non-interventional study where naloxegol is prescribed during normal clinical practice

Intervention type: DRUG
Intervention: non-PAMORA
Description: non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
Study: NCT04045821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: dilation and curettage
Description: all participants will undergo routine D\&C procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dilation and curettage
Description: all participants will undergo routine D\&C procedure
Study: NCT01076283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10mg t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyproheptadine
Description: 'active' placebo
Study: NCT03852966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-i/ADHD
Description: Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
Study: NCT03044522

Intervention type: OTHER
Group type: OTHER
Intervention: Opioid Education
Study: NCT02385019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
Description: Regulatory T cells selected by a sequential 2 step procedure:~1. - Negative selection of CD8 and CD19 cells~2. - Positive selection of CD25 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
Description: Regulatory T cells selected by a sequential 2 step procedure:~1. - Negative selection of CD8 and CD19 cells~2. - Positive selection of CD25 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
Description: Regulatory T cells selected by a sequential 2 step procedure:~1. - Negative selection of CD8 and CD19 cells~2. - Positive selection of CD25 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease
Description: Regulatory T cells selected by a sequential 2 step procedure:~1. - Negative selection of CD8 and CD19 cells~2. - Positive selection of CD25 cells
Study: NCT01412190

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane Vital Light
Description: Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: One side of face, one hand and one side of the décolletage is left untreated as a control.
Study: NCT01804790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfirinox
Description: Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on the center's choice.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 50 Gy
Description: 5 radiations per week of 2 Gy for 5 weeks
Study: NCT01852331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGD granules
Description: The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
Study: NCT01804790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 50 Gy
Description: 5 radiations per week of 2 Gy for 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1600 mg/m² (800 mg/m² twice daily) for 5 weeks
Study: NCT04191109

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study in which the amount of therapy performed during the rehabilitation program will be registered.Data regarding feasibility and safety of the program will be also recorded. Indeed, functional, cognitive and quality of life outcomes will be assessed.
Study: NCT01069575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides
Description: Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
Study: NCT04313569

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic menisctomy
Description: Arthroscopic medial menisctomy
Study: NCT03821337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Trans Magnetic Stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland \& Howard, 2014).
Study: NCT03312608

Intervention type: DIAGNOSTIC_TEST
Intervention: Navigated transcranial magnetic stimulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Navigated transcranial magnetic stimulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Navigated transcranial magnetic stimulation
Study: NCT01235572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Undergo early discharge and standard outpatient care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: Undergo early discharge and standard outpatient care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT01954368

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse.
Study: NCT04586413

Intervention type: OTHER
Intervention: No intervention - quality of life measure
Description: Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months

Intervention type: OTHER
Intervention: No intervention - quality of life measure
Description: Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months

Intervention type: OTHER
Intervention: No intervention - quality of life measure
Description: Participants will be part of the creation of a Post-COVID-19 quality of life measure if involved in Phase One. In Phase Two participants will complete this post-COVID-19 quality of life measure monthly for 12 months
Study: NCT03561337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROTEIN-CARBOHYDRATE
Description: PRO before and PRO-CHO after training

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CARBOHDYRATE
Description: CHO before and after training
Study: NCT02699606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
Study: NCT03891667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disulfiram
Description: Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Patients will receive disulfiram for 4 weeks followed by placebo for 4 weeks or disulfiram for 8 weeks.
Study: NCT03095274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab, 1500 mg Q4W for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
Study: NCT03352258

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiotherapy
Description: 10 Gy in 5 fractions of 2 Gy on 5 consecutive days
Study: NCT03813407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level
Description: Sodium Zirconium Cyclosilicate (SZC) Dose: Paediatric dose based on body weight equivalent to an adult 2.5 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)
Description: Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)
Description: Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)
Description: Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 15 g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
Description: A 28-day period during which SZC is administered orally once daily (QD) to maintain normokalaemia. A dose titration regimen starting with QD administration of the dose of SZC the participants received TID in the CP will be studied in the MP and continued in the LTMP. The maximum dose that can be used is the calculated body weight equivalent to the 15 g adult dose
Study: NCT00606346

Intervention type: BIOLOGICAL
Intervention: Anti TNF therapy including infliximab
Description: Treatments will be prescribed according to investigator judgement.

Intervention type: DRUG
Intervention: No Biologics
Description: Treatments will be prescribed according to investigator judgement.
Study: NCT01804790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1600 mg/m² (800 mg/m² twice daily) for 5 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TME surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfox6 or capecitabine
Description: oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfox6 or capecitabine
Description: oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 400 mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
Study: NCT04660994

Intervention type: OTHER
Intervention: Educational game
Description: The Yapouni educational game is based on a hot air balloon that will fly according to the number of hours the child has slept with his/her CPAP / NIV. Thus, the longer the child sleeps with his/her CPAP / NIV, the farther and higher his/her hot air balloon will fly in the sky. The game includes wild cards and rewards that are worked out with the child and his/her parents for an optimal individualized adaptation.~The game is explained at Necker Hospital during the therapy education for CPAP/NIV and used at home for 1 month.
Study: NCT03804424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-LLP2A
Description: -64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-LLP2A
Description: -64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: -All PET imaging will be performed as PET/MR or PET/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: -All PET imaging will be performed as PET/MR or PET/CT
Study: NCT03570632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy